SPN-812
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Attention-Deficit/Hyperactivity Disorder
Conditions
Attention-Deficit/Hyperactivity Disorder
Trial Timeline
Jan 23, 2020 → Dec 14, 2022
NCT ID
NCT04143217About SPN-812
SPN-812 is a phase 3 stage product being developed by Supernus Pharmaceuticals for Attention-Deficit/Hyperactivity Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT04143217. Target conditions include Attention-Deficit/Hyperactivity Disorder.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06185985 | Approved | Completed |
| NCT04786990 | Approved | Completed |
| NCT04143217 | Phase 3 | Completed |
| NCT02736656 | Phase 3 | Active |
Competing Products
18 competing products in Attention-Deficit/Hyperactivity Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| atomoxetine | Eli Lilly | Approved | 85 |
| Atomoxetine | Eli Lilly | Approved | 85 |
| Atomoxetine | Eli Lilly | Approved | 85 |
| Atomoxetine | Eli Lilly | Approved | 85 |
| ABT-089 + atomoxetine + placebo | AbbVie | Phase 2 | 52 |
| ABT-089 + Placebo | AbbVie | Phase 2 | 52 |
| ABT-089 | AbbVie | Phase 2 | 52 |
| ABT-089 + placebo | AbbVie | Phase 2 | 52 |
| MK0249 + Concerta (methylphenidate) + Placebo | Merck | Phase 2 | 52 |
| Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) + Placebo | Novartis | Approved | 85 |
| SPN-812 | Supernus Pharmaceuticals | Approved | 80 |
| IR Viloxazine + Placebo | Supernus Pharmaceuticals | Phase 1/2 | 36 |
| SPN-812 | Supernus Pharmaceuticals | Approved | 80 |
| 100mg SPN-812 + Placebo | Supernus Pharmaceuticals | Approved | 80 |
| Placebo + SPN-812 | Supernus Pharmaceuticals | Phase 3 | 72 |
| Placebo + 100mg SPN-812 + 200mg SPN-812 + 300mg SPN-812 + 400mg SPN-812 | Supernus Pharmaceuticals | Phase 2 | 47 |
| SPN-812 | Supernus Pharmaceuticals | Phase 3 | 72 |
| TD-9855 + TD-9855 + Placebo | Theravance Biopharma | Phase 2 | 47 |